Category: carcinoid syndrome

Patient & Caregiver Education on Carcinoid Syndrome: Talking to Your Doctor About Symptoms, Diet, and Treatment

Last Spring, we were pleased to create an interactive resource for people living with Carcinoid Syndrome with our partner CancerCoachLive – we’ve teamed …

Carcinoid Syndrome Web Series Continues with Presentation by Michael A. Morse, MD

The neuroendocrine tumor (NET) community is invited to attend a live national webcast by Michael A. Morse, MD (pictured below) on “Testing for Neuroendocrine Tumors and Carcinoid Syndrome” on Wednesday, September 13 at 7:00 pm EST, 6:00…

New Carcinoid Syndrome Web Series: Education, Testing and Nutrition

The neuroendocrine tumor (NET) community is invited to attend a new national webinar series on carcinoid syndrome, beginning on Wednesday, August 23, 2017 with a presentation by Eric H. Liu, MD, neuroendocrine surgeon at the Rocky Mountain Cancer …

Patient Education on Carcinoid Syndrome: From Diagnosis to Treatment

A Live Online Event on Wednesday, March 1, 11 am to 12 noon Eastern Standard Time

Ask Your Questions during the Live Program or Submit Them in Advance

Cancer Coach Live, in partnership with the Carcinoid Cancer Foundation, is presenting a special patient…

Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program

A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.

With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…

Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome

Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…

Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment

Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA).  LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …

Neuroendocrine Tumors Featured on Healthy Body, Healthy Mind Television Series

For a comprehensive overview of neuroendocrine tumors, watch this fascinating video on the Healthy Body, Healthy Mind television series. Every episode on the health and wellness TV series focuses on the stories of real people; people who are working…

WebMD Articles Raise Awareness about Carcinoid Cancer

Understanding carcinoid tumors, carcinoid syndrome, and treatments for carcinoid when surgery is not an option are the focus of three feature articles by Ellen Greenlaw on WebMD.com this month.  For these articles, Ms. Greenlaw sought the expertise…